Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F8CV
|
|||
| Former ID |
DNC005090
|
|||
| Drug Name |
DAMGO
|
|||
| Synonyms |
DAMGO; DAGO; glyol; Dagol; DAMGE; 78123-71-4; 2-Ala-4-mephe-5-gly-enkephalin; Tyr-ala-gly-(nme)phe-gly-ol; Enkephalin, ala(2)-mephe(4)-gly(5)-; RX 783006; (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin; Ala(2)-mephe(4)-gly-ol(5) enkephalin; CHEBI:272; CHEMBL38874; Tyr-D-Ala-Gly-MePhe-Gly-ol; Enkephalin, Ala(2)-MePhe(4)-Gly-ol(5)-; H-Tyr-D-Ala-Gly-N-Me-Phe-Glycinol; Enkephalin, alanyl(2)-methylphenylalanyl(4)-glycine(5)-; [3H]DAMGO; L-Phenylalaninamide, L-tyrosyl-D-alanylglycyl-N-(2-hydroxyethyl)-Nalpha-methyl-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H35N5O6
|
|||
| Canonical SMILES |
CC(C(=O)NCC(=O)N(C)C(CC1=CC=CC=C1)C(=O)NCCO)NC(=O)C(CC2=CC=C(C=C2)O)N
|
|||
| InChI |
1S/C26H35N5O6/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36)/t17-,21+,22+/m1/s1
|
|||
| InChIKey |
HPZJMUBDEAMBFI-WTNAPCKOSA-N
|
|||
| CAS Number |
CAS 78123-71-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:272
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Inhibitor | [2] |
| Opioid receptor kappa (OPRK1) | Target Info | Inhibitor | [3] | |
| Opioid receptor mu (MOP) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| cGMP-PKG signaling pathway | ||||
| Sphingolipid signaling pathway | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Opioid prodynorphin pathway | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1647). | |||
| REF 2 | Evaluation of N-substitution in 6,7-benzomorphan compounds. Bioorg Med Chem. 2010 Jul 15;18(14):4975-82. | |||
| REF 3 | Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4291-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.